XOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213
June 28 2016 - 9:01AM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today it has
initiated its Phase 2 proof-of-concept study for XOMA 213.
XOMA 213 (formerly referred to as LFA102) is a monoclonal
antibody that neutralizes prolactin induced signaling.
Prolactin is a protein that in normal post-partum females
enables the production of milk. In some cases, including
prolactinomas, which are benign tumors of the pituitary gland in
both men and women, excess secretion can lead to various clinically
significant abnormal signs and symptoms.
The open-label, mechanism of action,
single-dose, multi-center study is designed to evaluate two dose
levels of XOMA 213 in up to 35 subjects and confirm its ability to
curtail prolactin signaling. The study will take place in
Spain and safety will be monitored throughout.
“By initiating this mechanism of action study
for XOMA 213, we bring a second endocrine-focused asset into
mid-stage development,” said Paul Rubin, M.D., Senior Vice
President, Research and Development, and Chief Medical Officer at
XOMA. “Prolactinomas, which are benign tumors of the
pituitary gland, have serious medical consequences, particularly
infertility and osteoporosis. Ten to twenty percent of
patients do not respond to or are intolerant of current standard of
care medications. Based upon the results from this
proof-of-concept study, we will be able to determine the value of
further developing this antibody for treating patients with
symptomatic hyperprolactinemia.”
About XOMA CorporationXOMA
Corporation is a leader in the discovery and development of
therapeutic antibodies. The Company's innovative product
candidates result from its expertise in developing ground-breaking
monoclonal antibodies, including allosteric antibodies, which have
created new opportunities to potentially treat a wide range of
human diseases. XOMA's scientific research has produced a portfolio
of five endocrine assets, each of which has the opportunity to
address multiple indications. The Company's lead product
candidate, XOMA 358, is an allosteric monoclonal antibody that
reduces insulin receptor activity, which could have a major impact
on hyperinsulinism. The Company recently initiated Phase 2
development activities for XOMA 358 in patients with congenital
hyperinsulinism and in patients who experience hypoglycemia
following gastric bypass surgery. For more information, visit
www.xoma.com.
Forward-Looking
StatementsCertain statements contained in this press
release including, but not limited to, statements related to
anticipated timing of clinical trials, anticipated timing of the
release of clinical data, regulatory approval of unapproved product
candidates, the anticipated process of clinical data analysis, the
anticipated success of any clinical trial, cash usage, or
statements that otherwise relate to future periods are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements are based on assumptions that may not
prove accurate, and actual results could differ materially from
those anticipated due to certain risks inherent in the
biotechnology industry and for companies engaged in the development
of new products in a regulated market. Potential risks to XOMA
meeting these expectations are described in more detail in XOMA's
most recent filing on Form 10-K and in other SEC filings. Consider
such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date.
XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Taryn Ibach
W2O Group
415-658-9748
tibach@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024